ArticleAdvances in therapy2025
Challenges and Opportunities for Improving Management of Patients with nAMD and DME in China: Insights from a Global Survey on Anti-VEGF Therapy.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of ranibizumab, aflibercept, and conbercept in the treatment of diabetic macular edema: a retrospective comparative study.Scientific reports · 2026Article
- Choriocapillaris Flow Signal Deficits Are Associated With AMD Onset and Early Progression Over Three Years: ALSTAR2 Follow-Up.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis survey investigated the challenges and opportunities during anti-vascular endothelial growth factor (VEGF) therapy in Chinese patients.
methodsThe survey was conducted in six hospitals from different regions in China, as part of the Barometer global survey. Paper-based optical mark recognition (OMR) questionnaires were answered by 498 and 527 patients who had been diagnosed with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), respectively, and were currently receiving or had previously received anti-VEGF injections, and by physicians who prescribe and/or administer anti-VEGF injections for the treatment of nAMD/DME. A total of 105 nAMD physicians and 105 DME physicians completed the questionnaire.
resultsMore than half of patients with DME (60.7%) and doctors (69.5%) identified long periods of waiting during the appointment as a challenge. Over 85% of physicians and 55% of patients identified the limitation on number of treatments covered by insurance plans as another main challenge. The main opportunities to improve patient care agreed upon by physicians and patients were the provision of financial assistance with drug/prescription costs and lifting of reimbursement restrictions (84.3-94.3%), less frequent appointments, longer time in between treatments without compromising vision (82.9-95.2%), and increasing predictability of the injection schedule (83.9-95.2%). Over 90% of doctors and patients agreed that more time for doctors to answer questions/concerns during each appointment is an important need to strengthen communication.
conclusionLifting reimbursement limits, reducing appointments and extending the time between treatments without compromising vision, and increasing the time available to answer patient questions at each visit are key opportunities to improve patients' adherence and persistence for anti-VEGF therapy.
Indexed as
Identifiers
40576874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.